https://doi.org/10.4081/mm.2024.13226
Decrease of cefiderocol in vitro activity against carbapenemases-producing Gram-negative bacteria
Published: 3 December 2024
Abstract Views: 19
PDF: 24
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Not available.
Klein S, Boutin S, Kocer K, Fiedler MO, Störzinger D, Weigand MA, Tan B, Richter D, Rupp C, Mieth M, Mehrabi A, Hackert T, Zimmermann S, Heeg K, Nurjadi D. Rapid development of Cefiderocol resistance in carbapenem-resistant Enterobacter cloacae during therapy is associated with heterogeneous mutations in the catecholate siderophore receptor cirA. Clinical Infectious Diseases, 2022:74 (1 March).
DOI: https://doi.org/10.1093/cid/ciab511
Malik S, Kaminski M, Landman D, Quale J. Cefiderocol resistance in Acinetobacter baumannii: roles of beta-lactamases, siderophore receptors, and penicillin binding protein 3. Antimicrobial Agents and Chemotherapy, November 2020 Volume 64 Issue 11
DOI: https://doi.org/10.1128/AAC.01221-20
How to Cite
Bracco, S., Mercato, A., Lacavalla, M., Cerro, A., Campanini, S., Genovesi, A., & Farina, C. (2024). Decrease of cefiderocol <i>in vitro</i> activity against carbapenemases-producing Gram-negative bacteria. Microbiologia Medica, 39(2). https://doi.org/10.4081/mm.2024.13226
Copyright (c) 2024 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.